CN108601787B - 用于治疗恶性肿瘤的组合疗法 - Google Patents

用于治疗恶性肿瘤的组合疗法 Download PDF

Info

Publication number
CN108601787B
CN108601787B CN201680072973.3A CN201680072973A CN108601787B CN 108601787 B CN108601787 B CN 108601787B CN 201680072973 A CN201680072973 A CN 201680072973A CN 108601787 B CN108601787 B CN 108601787B
Authority
CN
China
Prior art keywords
compound
azacitidine
day
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680072973.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108601787A (zh
Inventor
维韦克·萨罗杰·库马尔·乔普拉
乔治·德马蒂诺
劳里·A·肯文
罗伯特·道格拉斯·奈特
凯尔·麦克白
克里希南·维斯瓦纳汉
许强
塞缪尔·V·阿格雷斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Celgene Corp
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of CN108601787A publication Critical patent/CN108601787A/zh
Application granted granted Critical
Publication of CN108601787B publication Critical patent/CN108601787B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680072973.3A 2015-10-15 2016-10-14 用于治疗恶性肿瘤的组合疗法 Active CN108601787B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242218P 2015-10-15 2015-10-15
US62/242,218 2015-10-15
PCT/US2016/057102 WO2017066611A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
CN108601787A CN108601787A (zh) 2018-09-28
CN108601787B true CN108601787B (zh) 2022-07-29

Family

ID=57219007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072973.3A Active CN108601787B (zh) 2015-10-15 2016-10-14 用于治疗恶性肿瘤的组合疗法

Country Status (16)

Country Link
US (2) US10695352B2 (enExample)
EP (1) EP3362070B1 (enExample)
JP (1) JP6895956B2 (enExample)
KR (1) KR102701893B1 (enExample)
CN (1) CN108601787B (enExample)
AU (1) AU2016340098B2 (enExample)
BR (1) BR112018007447B1 (enExample)
CA (1) CA3002029A1 (enExample)
CL (1) CL2018000955A1 (enExample)
EA (1) EA036129B1 (enExample)
ES (1) ES2862730T3 (enExample)
IL (1) IL258580B (enExample)
MX (1) MX381582B (enExample)
SG (2) SG11201802964QA (enExample)
WO (1) WO2017066611A1 (enExample)
ZA (1) ZA201802420B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206601B2 (en) 2013-12-09 2019-02-19 Medtronic, Inc. Noninvasive cardiac therapy evaluation
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
US11219769B2 (en) 2016-02-26 2022-01-11 Medtronic, Inc. Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing
KR102498693B1 (ko) 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
CN119280245A (zh) * 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
WO2019191602A1 (en) 2018-03-29 2019-10-03 Medtronic, Inc. Left ventricular assist device adjustment and evaluation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
WO2020257671A1 (en) 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US11497431B2 (en) 2019-10-09 2022-11-15 Medtronic, Inc. Systems and methods for configuring cardiac therapy
US12201843B2 (en) 2019-10-09 2025-01-21 Medtronic, Inc. Synchronizing external electrical activity
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
WO2022192621A1 (en) * 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
WO2015006592A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
DK3782612T3 (da) * 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
PL2307002T3 (pl) * 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
EP2525790B1 (en) * 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PL2773360T3 (pl) * 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
WO2015006592A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
ZA201802420B (en) 2020-08-26
MX2018004599A (es) 2018-09-21
IL258580A (en) 2018-05-31
SG10201912869WA (en) 2020-02-27
KR20180064529A (ko) 2018-06-14
NZ741433A (en) 2024-07-26
CL2018000955A1 (es) 2018-09-14
MX381582B (es) 2025-03-12
BR112018007447A2 (en) 2018-10-23
SG11201802964QA (en) 2018-05-30
AU2016340098A1 (en) 2018-05-10
KR102701893B1 (ko) 2024-09-03
EA036129B1 (ru) 2020-10-01
US20180303840A1 (en) 2018-10-25
CA3002029A1 (en) 2017-04-20
EA201890961A1 (ru) 2018-11-30
JP6895956B2 (ja) 2021-06-30
WO2017066611A1 (en) 2017-04-20
US10695352B2 (en) 2020-06-30
EP3362070B1 (en) 2021-01-27
BR112018007447B1 (pt) 2023-12-05
JP2018535951A (ja) 2018-12-06
ES2862730T3 (es) 2021-10-07
US20210100805A1 (en) 2021-04-08
CN108601787A (zh) 2018-09-28
EP3362070A1 (en) 2018-08-22
IL258580B (en) 2021-05-31
AU2016340098B2 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
KR102701893B1 (ko) 악성종양을 치료하기 위한 조합 요법
CN108697698B (zh) 用于治疗恶性肿瘤的组合疗法
EP3383400B1 (en) Methods of treatment of malignancies
EP3419593B1 (en) Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP2019515889A (ja) （１ｓ，４ｓ）−４−（２−（（（３ｓ，４ｒ）−３−フルオロテトラヒドロ−２ｈ−ピラン−４−イル）アミノ）−８−（（２，４，６−トリクロロフェニル）アミノ）−９ｈ−プリン−９−イル）−１−メチルクロロヘキサン−１−カルボキサミドの固体形態及びその使用方法
HK1259245A1 (en) Combination therapy for treating malignancies
HK1259245B (en) Combination therapy for treating malignancies
JP2019528260A (ja) 骨髄異形成症候群の治療方法
BR122024000250B1 (pt) Uso de um inibidor de desidrogenase isocitrato1 (IDH1) mutante e um agente desmetilante
BR112018007656B1 (pt) Uso do inibidor de isocitrato desidrogenase 1 mutante (IDH1) e azacitidina
BR122024020713A2 (pt) Uso de composto em terapia de combinação para tratamento de doenças malignas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221223

Address after: new jersey

Patentee after: CELGENE Corp.

Patentee after: LES LABORATOIRES SERVIER

Address before: new jersey

Patentee before: CELGENE Corp.

Patentee before: AGIOS PHARMACEUTICALS, Inc.

TR01 Transfer of patent right